Theradiag: 2022 sales without surprises
The Group reported annual sales of 12.2 million euros for the 2022 financial year, up 9.7%, driven in particular by a strong performance in exports (excluding the USA), with growth of +23.3%.
In theranostics (the combination of treatment and diagnostics, which measures the efficacy of biotherapies in the treatment of chronic diseases, and enables them to be properly implemented), growth reached 10.1%
The historical in vitro diagnostics business posted sales growth of 9.2% to 5.8 million euros.
At December 31, 2022, Theradiag's cash position stood at 6.4 million euros, compared with 7.1 million euros at December 31, 2021, a level deemed 'in line with the company's business plan'.
Following its tender offer, which closed last week, Biosynex held more than 68.8% of Theradiag's capital and at least 68.6% of its voting rights, meaning that the minimum condition of the offer has been met.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction